2017 Keynote Speakers
Barbara Bain
|
David GallerDavid Galler is the son of Anton Galler and Zosia Minc, Polish Jewish immigrants to NZ in the late 1940s and early 1950s, both now deceased. He lives in Auckland with his partner with whom he has two adult children.
For the past 25 years he has worked as an intensive care specialist at Middlemore Hospital. In 2011 he became a Clinical Director at Ko Awatea and Chair of the Programme Committee of the annual APAC Forum. David has recently returned from spending a year, working in Samoa. Whilst there he established an intensive care service to better identify and effectively manage infants children and others with acute reversible disease; as well as working with the National Health Service and National University of Samoa to establish in-country training for postgraduate medical education. During his career, he has held a number of leadership positions:
He is the author of “Things That Matter” his medical memoir published by Allen and Unwin, described by Unity Books Auckland as ‘the surprise hit of 2016”. |
Miles Prince
Miles Prince is a Haematologist and Professor/Director of Molecular Oncology and Cancer Immunology at Epworth Health Care and Director of the Centre for Blood Cell Therapy at Peter MacCallum Cancer Centre. His research focuses on clinical translational aspects of cancer immunology, genomics and epigenetics.
Miles holds national and international grants and has led numerous clinical trials of new agents in myleoma, lymphoma and leukaemia. He is Director at the Snowdome Foundation, the International Society of Cutaneous Lymphoma and the Myeloma Foundation and the LymphomaHub. He has published over 390 journal articles and his work has been recognised with an Order of Australia. |
Wyndham Wilson, M.D., Ph.D.Dr. Wilson obtained his MD and PhD and completed his medical residency at Stanford University. Following a fellowship in Medical Oncology at the National Cancer Institute, Dr. Wilson joined the faculty of the NCI as the Special Assistant to the Director, and later as a principal investigator. Dr. Wilson is currently the Chief, Hematological Malignancies Therapeutics Section, Metabolism Branch, Cancer Research Center, NCI.
His interests are in the study of the biology and treatment of lymphoid malignancies and he directs phase I, II and III translational studies. His work has focused on targeted treatments and the development of new therapeutic strategies. He has a special interest in the treatment of diffuse large B-cell lymphoma and EBV-driven lymphoproliferative disorders. He has developed new curative treatments for subtypes of large cell lymphoma, Burkitt lymphoma and Lymphomatoid Granulomatosis. He has received numerous awards for his work. Currently he chairs multiple national committees including the Oncology Drug Advisory Committee (ODAC) for the FDA. |